First Republic Investment Management Inc. lowered its stake in Becton Dickinson and Co (NYSE:BDX) by 6.6% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 87,276 shares of the medical instruments supplier’s stock after selling 6,189 shares during the period. First Republic Investment Management Inc.’s holdings in Becton Dickinson and were worth $22,779,000 as of its most recent SEC filing.
Several other large investors also recently made changes to their positions in the business. BlackRock Inc. lifted its position in shares of Becton Dickinson and by 1.3% in the third quarter. BlackRock Inc. now owns 19,029,060 shares of the medical instruments supplier’s stock worth $4,966,582,000 after buying an additional 253,041 shares during the last quarter. FMR LLC lifted its position in shares of Becton Dickinson and by 8.0% in the third quarter. FMR LLC now owns 17,354,031 shares of the medical instruments supplier’s stock worth $4,529,401,000 after buying an additional 1,286,579 shares during the last quarter. Fundsmith Equity Fund L.P. acquired a new stake in shares of Becton Dickinson and in the second quarter worth about $894,775,000. Wells Fargo & Company MN lifted its position in shares of Becton Dickinson and by 0.8% in the third quarter. Wells Fargo & Company MN now owns 3,565,101 shares of the medical instruments supplier’s stock worth $930,491,000 after buying an additional 27,188 shares during the last quarter. Finally, Putnam Investments LLC lifted its position in shares of Becton Dickinson and by 0.5% in the second quarter. Putnam Investments LLC now owns 3,513,485 shares of the medical instruments supplier’s stock worth $841,690,000 after buying an additional 18,859 shares during the last quarter. 85.19% of the stock is owned by institutional investors.
In related news, EVP James C. Lim sold 5,189 shares of the business’s stock in a transaction dated Thursday, November 8th. The stock was sold at an average price of $242.36, for a total transaction of $1,257,606.04. Following the transaction, the executive vice president now directly owns 13,318 shares in the company, valued at $3,227,750.48. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Timothy M. Ring sold 42,000 shares of the business’s stock in a transaction dated Wednesday, November 7th. The shares were sold at an average price of $237.07, for a total value of $9,956,940.00. Following the transaction, the director now owns 93,688 shares in the company, valued at $22,210,614.16. The disclosure for this sale can be found here. Insiders have sold 81,795 shares of company stock worth $19,571,318 over the last 90 days. Corporate insiders own 1.00% of the company’s stock.
NYSE BDX opened at $234.44 on Friday. Becton Dickinson and Co has a twelve month low of $209.91 and a twelve month high of $265.87. The company has a quick ratio of 0.69, a current ratio of 1.03 and a debt-to-equity ratio of 0.90. The stock has a market cap of $64.71 billion, a P/E ratio of 21.29, a price-to-earnings-growth ratio of 1.67 and a beta of 1.21.
Becton Dickinson and (NYSE:BDX) last posted its quarterly earnings data on Tuesday, November 6th. The medical instruments supplier reported $2.93 earnings per share for the quarter, hitting the consensus estimate of $2.93. Becton Dickinson and had a return on equity of 13.88% and a net margin of 1.47%. The business had revenue of $4.40 billion during the quarter, compared to analysts’ expectations of $4.36 billion. During the same quarter in the previous year, the firm earned $2.40 EPS. The firm’s revenue was up 39.0% compared to the same quarter last year. As a group, analysts expect that Becton Dickinson and Co will post 12.1 EPS for the current year.
The company also recently declared a quarterly dividend, which will be paid on Monday, December 31st. Investors of record on Monday, December 10th will be paid a dividend of $0.77 per share. This represents a $3.08 annualized dividend and a yield of 1.31%. This is a positive change from Becton Dickinson and’s previous quarterly dividend of $0.75. The ex-dividend date of this dividend is Friday, December 7th. Becton Dickinson and’s payout ratio is currently 27.25%.
Several equities analysts recently weighed in on BDX shares. Morgan Stanley boosted their price objective on Becton Dickinson and from $250.00 to $280.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 4th. Wells Fargo & Co boosted their price objective on Becton Dickinson and from $275.00 to $290.00 and gave the stock an “outperform” rating in a research report on Thursday, September 6th. They noted that the move was a valuation call. Barclays started coverage on Becton Dickinson and in a research report on Monday, October 15th. They set an “equal weight” rating and a $278.00 price objective for the company. KeyCorp boosted their price objective on Becton Dickinson and from $264.00 to $273.00 and gave the stock an “overweight” rating in a research report on Thursday, November 8th. Finally, Citigroup cut their price objective on Becton Dickinson and from $289.00 to $279.00 and set a “buy” rating for the company in a research report on Tuesday, November 13th. Six equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $255.53.
ILLEGAL ACTIVITY NOTICE: This report was first posted by American Banking News and is the property of of American Banking News. If you are reading this report on another domain, it was stolen and republished in violation of international copyright law. The original version of this report can be read at https://www.americanbankingnews.com/2018/12/08/first-republic-investment-management-inc-trims-position-in-becton-dickinson-and-co-bdx.html.
Becton Dickinson and Profile
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.
Read More: Stock Symbols and CUSIP Explained
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.